Can We Predict Clinical Cardiotoxicity with Cardiac Biomarkers in Patients After Haematopoietic Stem Cell Transplantation?

Abstract

The long-term prognosis of patients after haematopoietic stem cell transplantation (HSCT) has greatly improved. Cardiac complications represent unresolved and potentially life-threatening conditions in these patients. We prospectively examined 37 consecutive patients with a median age of 28 years who underwent allogeneic HSCT. Biomarkers of cardiac injury were measured serially before the conditioning regimen, the first day after HSCT and then 14, 30, 90 and 180 days after HSCT. Echocardiography was performed before and 1 month after HSCT. Eleven patients (30%) had persistently increased NT-proBNP values, 14 patients (38%) had only transient elevations and 12 (32%) had no changes in NT-proBNP concentrations for a period exceeding 14 days after HSCT. Elevated NT-proBNP values at day 14 after HSCT remained an independent predictor of cardiotoxicity during the first 6 months after HSCT (P < 0.01). Patients with persistent elevations in NT-proBNP also had significant elevations in hs-cTnT concentrations (P < 0.01). Only patients with persistently increased NT-proBNP had a significant worsening in systolic and some diastolic echocardiographic parameters, and we observed in this group the highest values of both cardiomarkers during the 6-month period. Forty-five percent of these patients developed clinical manifestation of cardiotoxicity. Elevations in NT-proBNP concentrations at day 14 after HSCT can predict patients at risk of developing cardiac events during the first 6 months after HSCT. Simultaneous elevations of both cardiomarkers (NT-proBNP and hs-cTnT) persisting 14 days after HSCT had a sensitivity of 83% and a specificity of 80.69%.

Validation of shortened 2-day sterility testing of mesenchymal stem cell-based therapeutic preparation on an automated culture system

“…From the regulatory perspective all MSC-based products are classified as ATMPs. ATMPs reflect a complex and innovative class of biopharmaceuticals, as these products are highly research-driven, characterized by innovative manufacturing processes and high complexity (Flory and Reinhardt 2013;Maslova et al 2015;Roziakova et al 2015). The manufacture of ATMPs requires novel approaches to quality control procedures in comparison to standard stem cell grafts.…”

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers

“…Additionally, in a multi-variate analysis, an elevation of BNP at baseline significantly raised the odds of subsequent cardiac events [49]. Multiple other small studies have found an association between elevation in BNP or NT pro-BNP and left ventricular dysfunction [50][51][52][53][54]. Not all studies have indicated the clear ability of natriuretic peptides to detect cardiotoxicity during anthracycline-based chemotherapy [55••, 56, 57].…”

Evaluation of Systolic Dysfunction in Patients With Lymphoproliferative Disorders After Stem Cell Transplant: A Single Center Egyptian Experience.

“…Other approaches to mitigate the cardiotoxic impact of anthracyclines employ potentially cardioprotective medications, such as ACE inhibitors and beta blockers. Although promising data have been published recently, convincing evidence from large randomized and prospective trials is still needed 3 There are some limitations of our current analysis. First, this was a retrospective study from a single institution.…”

“…However, HSCT survivors are at risk of developing long term complications, and mortality rates remain four-to ninefold higher than in the general population 3 .…”

“…Evaluation of cardiac toxicity in patients includes consideration of biomarkers such as cardiac troponins and B-type natriuretic peptides, together with noninvasive imaging in the form of 2D-, 3D-, or strain echocardiography, multiple gated radionuclide angiography, quantitative gated blood-pool SPECT, or cardiac magnetic resonance imaging 3 .…”